Optimization of Lipid-Based Nanoparticles Formulation Loaded with Biological Product Using A Novel Design Vortex Tube Reactor via Flow Chemistry
DOI: https://doi.org/10.2147/ijn.s474775
IF: 7.033
2024-08-29
International Journal of Nanomedicine
Abstract:Kittipat Suwanpitak, 1 Kampanart Huanbutta, 2 Nopphon Weeranoppanant, 3 Pornsak Sriamornsak, 4, 5 Chonlada Panpipat, 1 Tanikan Sangnim 1 1 Faculty of Pharmaceutical Sciences, Burapha University, Chonburi, 20131, Thailand; 2 Department of Manufacturing Pharmacy, College of Pharmacy, Rangsit University, Pathum Thani, 12000, Thailand; 3 Department of Chemical Engineering, Faculty of Engineering, Burapha University, Chonburi, 20131, Thailand; 4 Department of Industrial Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, 73000, Thailand; 5 Academy of Science, the Royal Society of Thailand, Bangkok, 10300, Thailand Correspondence: Tanikan Sangnim, Faculty of Pharmaceutical Sciences, Burapha University, 169, Seansook, Muang, Chonburi, 20131, Thailand, Email Introduction: Lipid-based nanoparticles (LNPs) is increasingly recognized for their potential in drug delivery, offering protection to hydrophobic drugs from degradation. Industrial synthesis of LNPs, exemplified by Pfizer-BioNTech and Moderna mRNA vaccines, utilizes flow chemistry or microfluidics, showcasing its scalability. This study explores the utilization of a novel design reactor, the vortex tube reactor, within flow chemistry for LNPs synthesis, aiming to optimize its conditions and compare them with batch synthesis. Methods: LNPs were synthesized using the vortex tube reactor, incorporating bovine serum albumin (BSA) as a model drug in the aqueous phase, alongside 1.2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol in the organic phase. Design of experiments (DoE), specifically Box-Behnken design, was employed to optimize parameters, including X 1 : the flow rate ratio (10– 100 mL/min), X 2 : the aqueous-to-organic volumetric ratio (1:1– 10:1), and X 3 : the number of reactor units (1– 5 units). Responses evaluated encompassed physical properties and productivity. Optimized conditions were determined by minimizing particle size (Y 1 ), polydispersity index (Y 2 ), and zeta potential (Y 3 ), while maximizing entrapment efficiency (Y 4 ), drug loading (Y 5 ), and productivity (Y 5 ). Results: Results indicated that optimal conditions were achieved at X 1 of 100 mL/min, X 2 of 5.278, and X 3 of 1 unit. LNPs synthesized under these conditions exhibited favorable physical properties and productivity, with uniformity maintained across batches. The vortex tube reactor demonstrated superiority over batch synthesis, yielding smaller particles (166.23 ± 0.98 nm), more uniform nanoparticles (PDI 0.17 ± 0.01), and higher entrapment (67.75 ± 1.55%) and loading capacities (36.39 ± 0.83%), indicative of enhanced productivity (313.4 ± 12.88 mg/min). Conclusion: This study elucidates the potential of flow chemistry, particularly utilizing the vortex tube reactor, for large-scale LNPs formulation, offering insights into parameter relationships and advancing nanoparticle synthesis for drug delivery applications. Keywords: flow chemistry, lipid-based nanoparticles, nanoparticles synthesis, biological product Graphical Nanoparticles have transformed drug delivery, spanning sizes from 1 to 1000 nm. This innovation promises enhanced drug efficacy while minimizing side effects. These nanoparticles enable precise drug delivery to target cells, controlled release, and targeted distribution through surface modification with ligands. They are currently being developed as drug delivery systems for various substances and vaccines on the market, including AmBisome, DepoCyt, Doxil, Inflexal, Myocet, Pfizer-BioNTech vaccines, and Moderna mRNA vaccines. 1,2 Nanoparticles have garnered significant attention in drug delivery due to their unique properties, such as a high surface area-to-volume ratio, the ability to traverse biological barriers, and the capacity to encapsulate both hydrophobic and hydrophilic drugs. Various types of nanoparticles, including polymeric, inorganic, and lipid-based nanoparticles, have been developed for drug delivery applications. 3 Lipid-based nanoparticles (LNPs) constitute a subclass of nanoparticles composed primarily of lipids, which have garnered significant attention in recent years. LNPs present several advantages over alternative nanoparticle systems, including high stability, biocompatibility, and the capability to target specific cells or tissues. This targeted approach enhances drug efficacy while mitigating side effects. Moreover, the customization of LNPs through surface modification with targeting ligands further refines their specificity toward desired cells or -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology